These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26752468)

  • 1. Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.
    Harris KA; Horst S; Gadani A; Nohl A; Annis K; Duley C; Beaulieu D; Ghazi L; Schwartz DA
    Inflamm Bowel Dis; 2016 Feb; 22(2):397-401. PubMed ID: 26752468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
    Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn's disease: a retrospective chart review.
    Do P; Andersen J; Patel A; Semrin G; Sifuentes-Dominguez L; Luu P; Gurram B
    F1000Res; 2020; 9():316. PubMed ID: 34504690
    [No Abstract]   [Full Text] [Related]  

  • 8. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
    Khorrami S; Ginard D; Marín-Jiménez I; Chaparro M; Sierra M; Aguas M; Sicilia B; García-Sánchez V; Suarez C; Villoria A; Taxonera C; Velasco-Guardado A; Martínez-González J; Gisbert JP
    Inflamm Bowel Dis; 2016 Jul; 22(7):1662-9. PubMed ID: 27306072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort.
    Weaver KN; Gregory M; Syal G; Hoversten P; Hicks SB; Patel D; Christophi G; Beniwal-Patel P; Isaacs KL; Raffals L; Deepak P; Herfarth HH; Barnes EL
    Inflamm Bowel Dis; 2019 Mar; 25(4):767-774. PubMed ID: 30295784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.
    Kopylov U; Afif W; Cohen A; Bitton A; Wild G; Bessissow T; Wyse J; Al-Taweel T; Szilagyi A; Seidman E
    J Crohns Colitis; 2014 Nov; 8(11):1516-22. PubMed ID: 24996483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
    Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
    Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
    Bertrand V; El Haite A; Carré D
    Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
    J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
    Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Grimaud JC; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):242-50.e1-2. PubMed ID: 26432476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Serrero M; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):588-595. PubMed ID: 29315694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn's Disease.
    Ren H; Kang J; Wang J; Su J; Zou L; Yin A; Li J; Zhou Q; Wang W; Tang Z; Zhang J; Lu Y; Yang Y; Qiu C; Ding Y; Dong W; An P
    Inflamm Bowel Dis; 2024 Aug; 30(8):1295-1302. PubMed ID: 37619248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Gutiérrez A; Antolín B; Huguet JM; De Francisco R; Merino O; Carpio D; García-López S; Mesonero F; Navarro P; Ferreiro-Iglesias R; Carbajo AY; Rivero M; Gisbert JP; Piñero-Pérez MC; Monfort D; Bujanda L; García-Sepulcre MF; Martín-Cardona A; Cañete F; Taxonera C; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):278-288. PubMed ID: 31222872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.